SCHEMBL6017939

SCHEMBL6017939

CCOC(=O)c1nc(-c2c(F)cccc2F)n(C)c(=O)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 5/20 0.43
ERCC1 P07992 1/20 0.42
FEN1 P39748 1/20 0.42
ERCC4 Q92889 1/20 0.42
TRPV4 Q9HBA0 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
CYP1A2 P05177 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
RAB9A P51151 2/20 0.40
MAPT P10636 1/20 0.40
POLB P06746 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GAA P10253 2/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018109 0.88 TRPV4 (0.35) KDM4EALDH1A1ERCC1FEN1ERCC4
SCHEMBL6018107 0.85 POLB (0.39) KDM4EALDH1A1ERCC1FEN1ERCC4
SCHEMBL19356983 0.85 NPSR1 (0.47) ALDH1A1NPSR1CYP1A2RAB9ANPC1
SCHEMBL6017918 0.84 CRHR1 (0.51) KDM4EALDH1A1ERCC1FEN1ERCC4
SCHEMBL6017629 0.77 LMNA (0.48) KDM4EALDH1A1ERCC1FEN1ERCC4
SCHEMBL6018051 0.76 ALDH1A1 (0.44) KDM4EALDH1A1ERCC1FEN1ERCC4
SCHEMBL6017708 0.75 KCNE1 (0.48) ALDH1A1NPSR1RXFP1POLBLMNA
SCHEMBL6017627 0.75 KCNE1 (0.54) ERCC1FEN1ERCC4POLBLMNA
SCHEMBL6018492 0.74 GABRG2 (0.42) KDM4EALDH1A1CYP1A2RAB9ANPC1
SCHEMBL6017839 0.74 SCD (0.46) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed
WO-2004096128-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS KDM4E 736/4885ALDH1A1 633/4885ERCC1 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.